[Blood hyperviscosity syndromes. Classification and physiopathological understanding. Therapeutic deductions]
- PMID: 6360007
[Blood hyperviscosity syndromes. Classification and physiopathological understanding. Therapeutic deductions]
Abstract
Blood has a number of rheological properties which partially determine flow, especially at capillary level, and its capacity to deliver oxygen. It is non-Newtonian, pseudoplastic, thixotropic and viscoelastic. Viscosity can be studied with different types of viscosimeters (coaxial cylinder or capillary viscosimeters). It can be defined by the ratio of stress of deformation to rate of deformation. Viscosity depends on macrorheological parameters: hematocrit, serum proteins, especially fibrinogen and globulins, and also on microrheological parameters: degree of aggregation and red blood cell deformability. Viscosity rises when the temperature falls and decreases with the radius of the tube through which the blood flows (Fahraeus-Linqvist effects). Blood viscosity is studied clinically at different temperatures, and, above all, at different rates of deformation by carefully recording the hematocrit. Plasma viscosity, fibrinogen, albumia and immunoglobulin levels, the viscosity of blood cell suspensions in normal saline must also be taken into consideration. Special investigations (rheoscopy, filtrability) provide information about red cell aggregation and deformability. Hyperviscosity syndromes are observed with: --raised hematocrit (polycythemia and pseudopolycythemia), --conditions with raised serum proteins or changes in their composition (especially hyperfibrinogenemia, raised immunoglobulins, low albumin levels); inflammatory syndromes, dysglobulinemias (Fahey's syndrome of plasma hyperviscosity), --low temperature (hypothermia), --increased red cell aggregability (shock, fat embolism), --reduced red cell deformability due to various congenital and acquired conditions (sickle cell anemia, renal failure, hyperlipoproteinemia, thrombosis, diabetes). Conversely, hypoviscosity may occur with a low hematocrit, hypoproteinemia, hypofibrinogenemia, and hyperthermia. Increased viscosity results in a slowing of blood flow, stagnation of its constituents and in ischemia. Therapeutic interventions may be considered on the different components of the hyperviscosity syndrome: hemodilation, plasmapheresis, dispersion of aggregants, agents acting on red cell deformability.
Similar articles
-
[Blood viscosity. Measurement and applications (hyper--and hypoviscosity syndromes) (author's transl)].Nouv Presse Med. 1981 Apr 18;10(17):1411-5. Nouv Presse Med. 1981. PMID: 7232152 French.
-
New trends in clinical hemorheology: an introduction to the concept of the hemorheological profile.Schweiz Med Wochenschr Suppl. 1991;43:41-9. Schweiz Med Wochenschr Suppl. 1991. PMID: 1843037 Review.
-
[Flow characteristics of blood and its therapeutic modification].Schweiz Med Wochenschr. 1987 May 2;117(18):693-7. Schweiz Med Wochenschr. 1987. PMID: 3589626 German.
-
[Hemodilution and plasmapheresis in the therapy of hyperviscosity syndromes].Ric Clin Lab. 1983;13 Suppl 3:225-44. Ric Clin Lab. 1983. PMID: 6424221 Italian.
-
[Classification and physiopathology of the hyperviscosity syndrome].Journ Annu Diabetol Hotel Dieu. 1983:179-97. Journ Annu Diabetol Hotel Dieu. 1983. PMID: 6358611 Review. French. No abstract available.
Cited by
-
Whole blood viscosity assessment issues IV: Prevalence in acute phase inflammation.N Am J Med Sci. 2010 Aug;2(8):353-8. doi: 10.4297/najms.2010.2353. N Am J Med Sci. 2010. PMID: 22737672 Free PMC article.
-
Blood Viscosity Changes in Diabetes Mellitus: A 20-Year Bibliometric Review and Future Directions.Cureus. 2024 Jul 10;16(7):e64211. doi: 10.7759/cureus.64211. eCollection 2024 Jul. Cureus. 2024. PMID: 39130872 Free PMC article. Review.
-
Whole blood viscosity assessment issues II: Prevalence in endothelial dysfunction and hypercoagulation.N Am J Med Sci. 2010 Jun;2(6):252-7. doi: 10.4297/najms.2010.2252. N Am J Med Sci. 2010. PMID: 22574299 Free PMC article.
-
Prevalence of anemia and risk of adverse bleeding effect of drugs: implication for therapy.Anemia. 2012;2012:795439. doi: 10.1155/2012/795439. Epub 2012 Feb 28. Anemia. 2012. PMID: 22506109 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical